Hepatitis C Medication - MyDekla Daclatasvir Dihydrochloride Tablets 60 Mg
Mydekla is indicated in combination other medicinal products for
the treatment of chronic hepatitis C virus (HCV) infection in adults.
Mydekla (Daclatasvir) is used with sofosbuvir 400 mg IP to treat
hepatitis C virus.
We are suppliers exporters of all types of Daclatasvir such
Mydekla ,Daclafab ,Hapcfix,Dacihep ,Hepcdac , natdac,
MyDacla,declafab,hepcifix, DalsiClear, Daclitof, Daclacure, DeciHep, Hepcdec.
MyDekla Medicine Details:-
- Brand Name: Mydekla
- Chemical salt: Daclatasvir
- Form: Tablets
- Strength: 60 Mg
- Packing: 1 X 28
- Manufactured by: Mylan Pharmaceuticals
Warning:-
Keep Mydekla medicine out of the reach and sight of children and
away from pets, never share your medicines with others, and use this medication
only for the indication prescribed. The information contained herein is not
intended to cover all possible uses, directions, precautions, warnings, drug
interactions, allergic reactions, or adverse effects.
Guidance and Advice:-
Mydekla medicine is a prescription drug and should be used under
proper medical guidance and advice. Do not share the Mydekla medicine with
others, since they may be suffering from a problem that is not effectively
treated by this drug.
If you have questions about the Mydekla drugs you are taking,
check with your doctor / Medical adviser / Nurse / Hospital Institution /
Health advisor or pharmacist.
Notice:-
The above information is an educational aid only. It is not
intended as medical advice for individual conditions or treatments. Talk to
your doctor, nurse or pharmacist before following any medical regimen to see if
it is safe and effective for you.
Contects us :-
Modern Times Helpline
Pharma
Address: Shop No.G, 7/31,Ground Floor Ansari Road
Darya Ganj New Delhi -
110002, INDIA.
Contact Person :Mr. Kamal Jindal
Mobile : +91-9899980831
Telephone No. : +91 - 011 - 43536395
Chat With Us :-
SKYPE: moderntimes-india
QQ: 1485238373
We chat Moderntimes-India
Whatsapp +91-9899980831

No comments:
Post a Comment